2. Academic Validation
  3. Chem-Bio Hybrid Synthesis Enables Reengineering of Natural Product-Based Methionine Aminopeptidase 2 Inhibitors for Treating Amebiasis

Chem-Bio Hybrid Synthesis Enables Reengineering of Natural Product-Based Methionine Aminopeptidase 2 Inhibitors for Treating Amebiasis

  • J Am Chem Soc. 2026 Feb 25;148(7):7189-7201. doi: 10.1021/jacs.5c18554.
Yuki Okura 1,  Yumiko Saito-Nakano 2,  Andrii Balia 3,  Nurul Syahmin Binti Suhaimi 3,  Chika Ando 1,  Namiko Ogata 4,  Tomona Ikeda 1,  Takumi Sato 4,  Keiko Kano 5,  Emi Mishiro-Sato 5,  Masaki Kita 1,  Noriyuki Miyoshi 6,  Kenji Watanabe 4,  Kouichi Yoshinari 4,  Norio Shibata 3,  Mihoko Mori 7,  Seiki Kobayashi 2,  Yuji Sumii 3,  Ryota Shizu 4,  Tomoyoshi Nozaki 8,  Yuta Tsunematsu 1
Affiliations

Affiliations

  • 1 Graduate School of Bioagricultural Sciences, Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8601, Japan.
  • 2 Department of Parasitology, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 162-8640, Japan.
  • 3 Department of Nanopharmaceutical Sciences and Department of Life Science and Applied Chemistry, Nagoya Institute of Technology, Nagoya 466-8555, Japan.
  • 4 School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.
  • 5 Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, Furo-cho, Chikusa, Nagoya, Aichi 464-8601, Japan.
  • 6 Graduate School of Integrated Pharmaceutical and Nutritional Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 422-8526, Japan.
  • 7 Graduate School of Agriculture, Tokyo University of Agriculture and Technology, Tokyo 183-8509, Japan.
  • 8 Department of Biomedical Chemistry, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0033, Japan.
PMID: 41631435 DOI: 10.1021/jacs.5c18554
Abstract

Natural products remain a vital source of therapeutic innovation, but their structural complexity often limits the systematic optimization and clinical translation. This challenge is exemplified by the Fungal metabolite fumagillin, a covalent inhibitor of methionine Aminopeptidase 2 (MetAP2), which advanced toward clinical development but whose semisynthetic derivatives were discontinued in trials for Cancer and obesity because of adverse effects. To overcome these barriers, we reengineered the fumagillin biosynthetic pathway in Aspergillus nidulans to expand chemical diversity, uncovering its natural analog ovalicin as a more potent agent active against Entamoeba histolytica. Although ovalicin had never been developed clinically, our analyses revealed that its rapid degradation by hepatic Cytochrome P450 enzymes underlies its therapeutic ineffectiveness in preclinical studies. We then established a chem-bio hybrid platform that integrates pathway-engineered biosynthesis with site-selective chemical derivatization to address this metabolic fragility. Introduction of a C6-hydroxyl group as a built-in functional handle enabled preparative-scale diversification and the synthesis of about 30 analogs. Several C6-modified derivatives maintained subnanomolar MetAP2 inhibition, resisted P450-mediated metabolism, and exhibited negligible cytotoxicity. Two optimized compounds, YOK24 and NS-181, achieved complete resolution of amebic liver abscess in hamsters after both subcutaneous and oral administration. Together, these findings establish a general and broadly applicable strategy for the biosynthetic reprogramming of natural products, providing a blueprint for expanding the chemical and therapeutic space of complex metabolites beyond conventional synthetic and biosynthetic limits.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z